See more : Evergreen Products Group Limited (1962.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Nanobac Pharmaceuticals, Incorporated (NNBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nanobac Pharmaceuticals, Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
- Banca IFIS S.p.A. (IF.MI) Income Statement Analysis – Financial Results
- Theradiag SA (ALTER.PA) Income Statement Analysis – Financial Results
- OboTech Acquisition SE (OTA.F) Income Statement Analysis – Financial Results
- JVL Agro Industries Limited (JVLAGRO.NS) Income Statement Analysis – Financial Results
- Kri-Kri Milk Industry S.A. (KRI.AT) Income Statement Analysis – Financial Results
Nanobac Pharmaceuticals, Incorporated (NNBP)
Industry: Biotechnology
Sector: Healthcare
About Nanobac Pharmaceuticals, Incorporated
Nanobac Pharmaceuticals, Incorporated discovers and develops products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). It manufactures and markets in vitro diagnostic (IVD) kits, such as assays, antibodies, and reagents for detecting CNPs. The company's diagnostic assays comprise NANO-CAPTURE and NANO-SERO. Additionally, it conducts research and clinical studies in the development of urological diseases, including chronic prostatitis/chronic pelvic pain syndrome, kidney stones, and polycystic kidney diseases, as well as cardiovascular diseases. Nanobac Pharmaceuticals, Incorporated was formerly known as HealthCentrics Inc. and changed its name to Nanobac Pharmaceuticals, Incorporated in December 2002. The company was founded in 1994 and is based in Tampa, Florida.
| Metric | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.62K | 225.09K | 656.80K | 358.36K | 482.82K | 11.56K | 6.84M | 8.77M | 9.94M | 8.88M | 6.20M | 3.70M |
| Cost of Revenue | 14.52K | 79.81K | 229.45K | 100.47K | 333.12K | 4.32K | 4.41M | 5.39M | 5.33M | 4.85M | 3.50M | 1.60M |
| Gross Profit | 3.10K | 145.28K | 427.36K | 257.89K | 149.69K | 7.24K | 2.43M | 3.39M | 4.61M | 4.03M | 2.70M | 2.10M |
| Gross Profit Ratio | 17.60% | 64.54% | 65.07% | 71.96% | 31.00% | 62.65% | 35.53% | 38.62% | 46.38% | 45.36% | 43.55% | 56.76% |
| Research & Development | 1.15M | 1.99M | 1.19M | 2.38M | 540.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.31M | 1.84M | 1.31M | 4.77M | 2.13M | 26.88K | 3.76M | 4.11M | 4.41M | 3.58M | 2.60M | 1.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 4.92M | 4.96M | 3.27M | 7.86M | 2.85M | 1.48M | 4.80M | 5.44M | 5.85M | 4.79M | 3.50M | 1.60M |
| Cost & Expenses | 4.93M | 5.04M | 3.49M | 7.96M | 3.18M | 1.49M | 9.21M | 10.82M | 11.18M | 9.64M | 7.00M | 3.20M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 460.30K | 541.28K | 759.94K | 717.07K | 181.10K | -2.95M | 1.04M | 1.33M | 1.45M | 1.21M | 900.00K | 600.00K |
| EBITDA | -5.93M | -4.23M | -2.86M | -6.88M | -2.52M | -1.48M | -1.33M | -720.12K | 204.71K | 450.48K | 100.00K | 1.10M |
| EBITDA Ratio | -16,912.28% | -1,656.45% | -197.78% | -1,929.41% | -517.29% | -12,767.62% | -22.29% | -9.61% | 1.81% | 4.15% | -3.23% | 29.73% |
| Operating Income | 4.91M | 4.81M | 2.84M | 7.60M | 2.70M | 1.48M | 2.37M | 2.05M | 1.24M | 759.77K | -1.10M | 500.00K |
| Operating Income Ratio | 27,891.78% | 2,138.98% | 432.05% | 2,120.87% | 559.26% | 12,767.62% | 34.60% | 23.36% | 12.48% | 8.56% | -17.74% | 13.51% |
| Total Other Income/Expenses | -1.66M | -743.82K | -849.65K | -217.13K | -5.46M | -2.95M | -5.11M | -4.73M | -3.15M | -2.00M | -200.00K | 0.00 |
| Income Before Tax | -6.58M | -4.97M | -3.69M | -7.82M | -2.76M | -1.48M | -2.74M | -2.68M | -1.91M | -1.24M | -1.00M | 0.00 |
| Income Before Tax Ratio | -37,319.74% | -2,209.53% | -561.41% | -2,181.46% | -572.55% | -12,767.62% | -40.02% | -30.54% | -19.21% | -13.99% | -16.13% | 0.00% |
| Income Tax Expense | 1.66M | 158.82K | 849.65K | 274.40K | 999.28K | 0.00 | 370.99K | 629.29K | 669.35K | 481.89K | -200.00K | 400.00K |
| Net Income | -6.58M | -4.97M | -3.69M | -7.87M | -3.70M | -1.48M | -2.74M | -2.68M | -1.91M | -1.24M | -800.00K | 100.00K |
| Net Income Ratio | -37,319.74% | -2,209.53% | -561.41% | -2,197.44% | -766.23% | -12,767.62% | -40.02% | -30.54% | -19.21% | -13.99% | -12.90% | 2.70% |
| EPS | 0.00 | -0.02 | -0.02 | -0.05 | -0.05 | -0.07 | -1.23 | -1.21 | -2.42 | -1.93 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.02 | -0.02 | -0.05 | -0.05 | -0.04 | -1.23 | -1.21 | -2.42 | -1.93 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 0.00 | 199.43M | 188.86M | 152.90M | 67.49M | 19.98M | 2.22M | 2.22M | 789.97K | 644.85K | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 0.00 | 199.43M | 188.86M | 152.90M | 67.49M | 36.25M | 2.22M | 2.22M | 789.97K | 644.85K | 0.00 | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports